ALDVI Stock Overview
A specialty pharmaceutical company, develops, commercializes, and markets treatments for rare renal diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Advicenne S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.15 |
| 52 Week High | €3.08 |
| 52 Week Low | €0.83 |
| Beta | 1.11 |
| 11 Month Change | 9.44% |
| 3 Month Change | 116.89% |
| 1 Year Change | 10.57% |
| 33 Year Change | -73.65% |
| 5 Year Change | -77.66% |
| Change since IPO | -84.68% |
Recent News & Updates
Shareholder Returns
| ALDVI | FR Pharmaceuticals | FR Market | |
|---|---|---|---|
| 7D | 3.1% | -3.4% | -0.3% |
| 1Y | 10.6% | 6.2% | -3.5% |
Return vs Industry: ALDVI exceeded the French Pharmaceuticals industry which returned 6.2% over the past year.
Return vs Market: ALDVI exceeded the French Market which returned -2.5% over the past year.
Price Volatility
| ALDVI volatility | |
|---|---|
| ALDVI Average Weekly Movement | 31.4% |
| Pharmaceuticals Industry Average Movement | 3.7% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in FR Market | 9.2% |
| 10% least volatile stocks in FR Market | 2.2% |
Stable Share Price: ALDVI's share price has been volatile over the past 3 months compared to the French market.
Volatility Over Time: ALDVI's weekly volatility has increased from 21% to 31% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 21 | Didier Laurens | www.advicenne.com |
Advicenne S.A., a specialty pharmaceutical company, develops, commercializes, and markets treatments for rare renal diseases. Its main drug candidate is Sibnayal, which has completed phase III clinical trial for the treatment of distal renal tubular acidosis, as well as cystinuria. The company also distributes Likozam, a formulation of clobazam for the treatment of short-term symptomatic of severe, disabling, or condition-causing anxiety unacceptable distress; and Levidcen, a galenic form of levetiracetam for the treatment of epileptic seizures.
Advicenne S.A. Fundamentals Summary
| ALDVI fundamental statistics | |
|---|---|
| Market cap | €26.35m |
| Earnings (TTM) | -€8.83m |
| Revenue (TTM) | €3.33m |
7.9x
P/S Ratio-3.0x
P/E RatioIs ALDVI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALDVI income statement (TTM) | |
|---|---|
| Revenue | €3.33m |
| Cost of Revenue | €2.22m |
| Gross Profit | €1.11m |
| Other Expenses | €9.94m |
| Earnings | -€8.83m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.72 |
| Gross Margin | 33.33% |
| Net Profit Margin | -264.93% |
| Debt/Equity Ratio | -102.2% |
How did ALDVI perform over the long term?
See historical performance and comparison